Idenix initiates Phase 2 HCV trial, files patent infringement suits against Gilead

Idenix Pharmaceuticals (IDIX) starts patient enrollment in HELIX-2 — that's the DAA HCV combo comprising samatasvir and the JNJ co-developed protease inhibitor and polymerase inhibitor simeprevir and TMC647055.

The Phase 2 study will evaluate efficacy, safety and tolerability of the combo in treatment-naïve or relapsed (after interferon and ribavirin) GT1 HCV patients. (PR)

In other company news, IDIX has filed two patent infringement lawsuits against Gilead (GILD) tied to methods of treating the HCV using 2'-methyl nucleosides.

Here's IDIX: "[The company] is seeking a declaration that GILD's imminent distribution, importation, use, sale or offer to sell drugs containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents." (PR)

Comments (2)
  • rnn
    , contributor
    Comments (680) | Send Message
    Its selling off on the positive article/news.
    2 Dec 2013, 01:13 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (884) | Send Message
    a patent suit.. oh boy. Here we go. Patents are almost worthless in today's age
    2 Dec 2013, 03:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs